In a recent open-label trial, 17 patients with major depressive disorder attended a single dosing session with ayahuasca. Depression severity was assessed before, during and after dosing, using the Hamilton Depression Rating scale (HAM-D) and the Montgomery–Åsberg Depression Rating Scale (MADRS) (Sanches et al., 2016). Significant reduction in depression severity was found already in the first hours after dosing, an effect that remained significant for 21 days (Osório et al., 2015; Sanches et al., 2016). Although promising, these studies have not controlled for the placebo effect, which can be remarkably high in clinical trials for depression, reaching 30–40% of the patients (Sonawalla and Rosenbaum, 2002). To address this issue, and to further test the antidepressant effects of ayahuasca, we conducted a randomized placebo-controlled trial in patients with treatment-resistant depression. Additionally, we explored for correlations between the antidepressant and the acute effects of ayahuasca.
- On the road towards the 2019 Ministerial Segment
- Unlinked anonymous HIV and viral hepatitis monitoring among PWID: 2018 report
- Global Fund Partnership has Saved 27 Million Lives
- Crime, Drugs, and Power in Honduras: Searching for Better Measures of State Fragility
- Coca leaf: Myths and Reality
- Media reporting on substance use: Magnifying or reducing the harm?
- Speed limits: Harm reduction for people who use stimulants
- Model drug law for West Africa: A tool for policy makers
- OHCHR report: Implementation of the joint commitment to effectively addressing and countering the world drug problem with regard to human rights